{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:31:13Z","timestamp":1773408673613,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/mca.0000000000000392","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T16:29:37Z","timestamp":1464452977000},"page":"561-565","source":"Crossref","is-referenced-by-count":2,"title":["Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease"],"prefix":"10.1097","volume":"27","author":[{"given":"Sinisa","family":"Markovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiu","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Walcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Imhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"W\u00f6hrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","article-title":"A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial","volume":"385","author":"Serruys","year":"2015","journal-title":"Lancet"},{"key":"R2-7-20210204","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-7-20210204","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","article-title":"Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial","volume":"66","author":"Gao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R4-7-20210204","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","article-title":"A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan","volume":"36","author":"Takeshi","year":"2015","journal-title":"Eur Heart J"},{"key":"R5-7-20210204","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","article-title":"Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"R6-7-20210204","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.carrev.2012.09.003","article-title":"Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses","volume":"13","author":"Markovic","year":"2012","journal-title":"Cardiovasc Revasc Med"},{"key":"R7-7-20210204","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ccd.24409","article-title":"Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries","volume":"81","author":"W\u00f6hrle","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"R8-7-20210204","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/hrt.2011.226563","article-title":"Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease","volume":"97","author":"W\u00f6hrle","year":"2011","journal-title":"Heart"},{"key":"R9-7-20210204","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"R10-7-20210204","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV10I6A118","article-title":"Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial","volume":"10","author":"Zhang","year":"2014","journal-title":"EuroIntervention"},{"key":"R11-7-20210204","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4244\/EIJY14M12_10","article-title":"Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds","volume":"11","author":"W\u00f6hrle","year":"2015","journal-title":"EuroIntervention"},{"key":"R12-7-20210204","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","article-title":"Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds","volume":"65","author":"Puricel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R13-7-20210204","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.4244\/EIJV10I12A243","article-title":"The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled","volume":"10","author":"Abizaid","year":"2015","journal-title":"EuroIntervention"},{"key":"R14-7-20210204","first-page":"85","article-title":"Bioresorbable vascular scaffold thrombosis in an all-comer patient population: single-center experience","volume":"27","author":"Azzalini","year":"2015","journal-title":"J Invasive Cardiol"},{"key":"R15-7-20210204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacc.2011.02.022","article-title":"Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial","volume":"58","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R16-7-20210204","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:40:47Z","timestamp":1620960047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000392","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}